Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Other Accumulated Expenses (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Other Accumulated Expenses readings, the most recent being $668000.0 for Q4 2017.

  • On a quarterly basis, Other Accumulated Expenses rose 5466.67% to $668000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $668000.0, a 5466.67% increase, with the full-year FY2017 number at $668000.0, up 5466.67% from a year prior.
  • Other Accumulated Expenses hit $668000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $22000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q2 2017 to a low of $12000.0 in Q4 2016.
  • Median Other Accumulated Expenses over the past 5 years was $114000.0 (2016), compared with a mean of $227666.7.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 92.81% in 2016 and later skyrocketed 5466.67% in 2017.
  • Eledon Pharmaceuticals' Other Accumulated Expenses stood at $60000.0 in 2013, then surged by 175.0% to $165000.0 in 2014, then increased by 1.21% to $167000.0 in 2015, then tumbled by 92.81% to $12000.0 in 2016, then skyrocketed by 5466.67% to $668000.0 in 2017.
  • The last three reported values for Other Accumulated Expenses were $668000.0 (Q4 2017), $22000.0 (Q3 2017), and $1.3 million (Q2 2017) per Business Quant data.